Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Sees Large Increase in Short Interest

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totaling 10,469 shares, an increase of 101.0% from the March 15th total of 5,208 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 46,236 shares, the days-to-cover ratio is currently 0.2 days.

Barinthus Biotherapeutics Stock Performance

Barinthus Biotherapeutics stock opened at $0.57 on Tuesday. Barinthus Biotherapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.92. The firm’s fifty day moving average price is $0.61 and its 200-day moving average price is $0.82. The stock has a market cap of $23.45 million, a P/E ratio of -0.35 and a beta of -0.61.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its earnings results on Friday, March 13th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.13. On average, analysts predict that Barinthus Biotherapeutics will post -1.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $4.00.

Hedge Funds Weigh In On Barinthus Biotherapeutics

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Renaissance Technologies LLC lifted its holdings in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 115.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 143,100 shares of the company’s stock after purchasing an additional 76,800 shares during the period. Renaissance Technologies LLC owned about 0.35% of Barinthus Biotherapeutics worth $100,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.